Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Methamphetamine Use Disorder
NCT07509112Phase 2Not yet recruiting
- Sponsor
- The Kirby Institute
- Start
- Sep 2026
- Primary completion
- Jan 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in methamphetamine use disorder (MUD), sponsored by The Kirby Institute. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT07509112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07509112.